US$ 22.36
tirzepatide cardiovascular outcomes Real-World of Obesity Treatment With Versus Semaglutide in Non-Diabetic Adults In obese individuals without diabetes, tirzepatide was associated with a lower risk of cardiovascular events, especially incident HF Effects of tirzepatide on circulatory
Description
Noom Med: Partial

It contains the same active ingredient, semaglutide, and is administered weekly

Patient Preferences Some patients may prefer one medication over the other based on factors such as brand recognition, perceived efficacy, or personal experiences shared by others
However, determining the coverage for specific drugs and indications can be complex
